Clinical

Matthew J. Zirwas, MD, a dermatologist in Ohio, discusses how dermatologists may stratify patients with atopic dermatitis (AD) with the launch of new biologic treatments in 2021.

The top 5 most-read Parkinson disease stories of 2020 on AJMC.com included the latest insights on treatments such as spinal cord stimulation and the role of dietary management, as well as implications of the coronavirus disease 2019 pandemic.

Premature coronary artery disease (CAD) is an aggressive disease with a high rate of ischemic recurrences and premature death, researchers said.

This approach allows clinicians to keep using existing prediction models and incorporate chronic kidney disease (CKD) data seamlessly to calibrate patients' risks, said Kunihiro Matsushita, MD, an associate professor in the Department of Epidemiology and Division of Cardiology at Johns Hopkins University.

New research shows metabolic biomarkers could be meaningful tools for predicting treatment outcomes in patients, based on a comparison of biomarkers, clinical characteristics, and therapeutic efficacy.

A recent study sought to estimate the incidence of clinical events such as bleeding, myocardial infarction, and all-cause mortality in patients with acute myocardial infarction and chronic coronary syndrome who received dual antiplatelet therapy (DAPT) after coronary stenting.

Our 5 most-read oncology stories and most-watched videos this year highlighted cancer care policy, diversity, and the growing practice of remote cancer care.

Two story lines predominated renal news in 2020: coronavirus disease 2019's effect on the kidneys and the overwhelming benefits of sodium-glucose cotransporter 2 inhibitors for those with chronic kidney disease and type 2 diabetes.

The review of 32 studies revealed that biologic treatment tended to favor patients with allergic bronchopulmonary aspergillosis (ABPA) and asthma rather than those with cystic fibrosis (CF).

This year’s top 5 most-read stories in lung cancer were overrun by non–small cell lung cancer drug trial results and FDA action.

A study from Denmark found that low health literacy was not a risk factor for mortality in patients with chronic obstructive pulmonary disease (COPD) compared with the general population and patients with other chronic conditions.

Researchers sought to gain a better understanding of the relationship between genetic mutations in metastatic colon cancer (mCRC), advanced disease, and locations of primary tumors.

The FDA has approved Margenza (margetuximab-cmkb) plus chemotherapy as a treatment option for adults with HER2-postive advanced breast cancer.

Researchers explored the risk of cardiovascular disease (CVD) as it relates to factors like excess weight, disease evolution time, and clinical activity.

As a neurodegenerative disease, secondary progressive multiple sclerosis (SPMS) may lead to a degradation of cognition skills as the disease progresses.

Researchers review pulmonary function testing measures that span 4 categories that can assess the respiratory muscle dysfunction that happens in diseases like spinal muscular atrophy (SMA).

Researchers found abnormal coherence patterns in survivors of childhood polio.

The analysis reviewed the safety and efficacy among patients in Japan to confirm the findings of the overall study population.

Giving patients icosapent ethyl, or Vascepa, led to a 52% reduction of the total patient-reported symptom outcome prevalence score as compared with a 24% decline for outpatients who received usual care.

Physicians will soon have a more complex set of options when treating patients with multiple myeloma (MM), but the authors of a new review article argued clinicians will need to take a pragmatic approach.

Both clinical and physician-based factors play a role in the risk of a patient with hematologic malignancies ending up in the ICU.

A new study indicates that an analysis of serum and cerebrospinal fluid cytokine levels can identify multiple sclerosis and its forms.

A new meta-analysis finds high rates of efficacy and high rates of toxicity in multiple myeloma patients treated with B-cell maturation agent (BCMA)-targeted chimeric antigen receptor (CAR)- T cells.

A new study may help clear up questions about the superiority of venetoclax with hypomethylating agents in patients who are deemed to be at high risk of treatment-related mortality.